Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Sara Hua, APM
CONTACT
Wilson Wang, Head of Clinical Operation
CONTACT
Lead
Axter Therapeutics (Beijing) Co., Ltd
This study consists of two phases. The first phase (Phase Ia) is a safety lead-in study of AXT-1003 in combination with Enzalutamide; the second phase (Phase Ib) is a dose expansion study. Phase Ia is a non-randomized, open-label study designed to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of AXT-1003 in combination therapy. Based on data derived from the Phase Ia dose-escalation phase, two dose levels of AXT-1003 will be selected for an expansion study in combination with enzalutamide, to explore the antitumor activity.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted